MAIA Biotechnology, Inc. (MAIA)
(Delayed Data from AMEX)
$3.33 USD
-0.06 (-1.77%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $3.34 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
MAIA 3.33 -0.06(-1.77%)
Will MAIA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MAIA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MAIA
MAIA Soars 20% on Interim Results From Lung Cancer Study
Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now
MAIA: What are Zacks experts saying now?
Zacks Private Portfolio Services
MAIA Biotechnology, Inc. (MAIA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study
Other News for MAIA
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA reports THIO-101 data from third-line treatment shows ORR of 38%
MAIA Biotechnology Reports Progress in Cancer Drug Development